CellaVision AB
STO:CEVI
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
CellaVision AB
STO:CEVI
|
3.7B SEK |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.4B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
127.3B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.2B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.6B USD |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for CellaVision AB is 20.2%, which is above its 3-year median of 19.1%.
Over the last 3 years, CellaVision AB’s Net Margin has increased from 19.3% to 20.2%. During this period, it reached a low of 16% on Jun 30, 2023 and a high of 20.4% on Sep 30, 2024.
